glp-1 inhibitor for weight loss Reduction with Agonists and Paths Discontinuation While Maintaining Weight Nutritional priorities to support GLP-1

American talk show host Oprah Winfrey revealed in an interview with People last December that she had used Ozempic, Wegovy, and Mounjaro for weight loss, but said that other areas, including a fitness routine was important too

How Tirzepatide Compares Mechanistically to Semaglutide and Liraglutide | Feature | Tirzepatide | Semaglutide | Liraglutide | |---|---|---|---| | Receptor targets | GIP-R + GLP-1R | GLP-1R only | GLP-1R only | | Half-life | ~5 days | ~7 days | ~13 hours | | Dosing frequency | Weekly | Weekly | Daily | | Max approved weight loss dose | 15 mg | 2.4 mg (Wegovy) | 3 mg (Saxenda) | | Mean weight loss (key trial) | 20.9% (SURMOUNT-1) | 14.9% (STEP-1) | 5.8% (SCALE) | | Biased GLP-1R agonism | Yes (low beta-arrestin) | Partial | Lower | | Adipose GIPR mechanism | Yes | No | No | The 6-percentage-point gap in mean weight loss between tirzepatide and semaglutide in their respective Phase III key trials reflects the additive adipose and hypothalamic contributions of GIPR engagement [34]

EClinicalMedicine (2021) 34:100797

Chem Biol Drug Des

PMID: 35413689

Belln T, Lerma V, Gonzlez-Valle O, Gonzlez Herrada C, De Abajo FJ